TGFB1 and non-small cell lung carcinoma: These results indicate that combined treatment may enhance the efficacy of erlotinib in inducing NSCLC cell death and inhibit the TGF-β1–induced EMT process through the suppression of Smad and non-Smad Wnt/β-catenin signaling.